Ibio Inc Revenue Growth Rates (IBIO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ibio inc   (NASDAQ: IBIO)
 

IBIO's Revenue Growth by Quarter and Year

Ibio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IBIO/growth
https://api.csimarket.com/api/v1/companies/IBIO/fundamentals
https://api.csimarket.com/api/v1/companies/IBIO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IBIO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 1.08
FY 1.08

IBIOs Annual Revenue
Ibio Inc 's Revenue in the fiscal year 2026 $ 0.10 millions
Ibio Inc 's Revenue in the fiscal year 2025 $ 0.40 millions
Ibio Inc 's Revenue in the fiscal year 2024 $ 0.23 millions
Ibio Inc 's Revenue in the fiscal year 2023 $ 0.00 millions
Ibio Inc 's Revenue in the fiscal year 2022 $ 2.38 millions




IBIO Revenue first quarter 2026 Y/Y Growth Comment
Ibio inc achieved in the first quarter 2026, above Company average Revenue surge of 975% year on year, to $ 1.08 millions.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Revenue growth. While Ibio Inc ' s Revenue doubling of 975% ranks overall at the positon no. 54 in the first quarter 2026.


IBIO Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 975 %
FY   -

Financial Statements
Ibio Inc 's first quarter 2026 Revenue $ 1.08 millions IBIO's Income Statement
Ibio Inc 's first quarter 2025 Revenue $ 0.10 millions Quarterly IBIO's Income Statement


IBIO Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September -
FY (Year on Year)   -


Back to IBIO Growth rate Comparisons >> Back to IBIO Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #21
Overall #54

Revenue Y/Y Growth Statistics
High Average Low
1376.71 % 87.2 % -100 %
 
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #21
Overall #54
Revenue Y/Y Growth Statistics
High Average Low
1376.71 % 87.2 % -100 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ibio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IBIO's I. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IBIO's I. Quarter Q/Q Revenue Comment


Ibio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking #


Cumulative Revenue growth Comment
In the Sep 30 2026 period, Ibio Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Ibio inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Sep 30 2026 period, Ibio Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Ibio inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IBIO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Vivos Inc1,438.05%$ 1,438.052 millions
Crispr Therapeutics Ag1,325.08%$ 1,325.084 millions
Ibio inc 975.00%$ 975.000 millions
Sintx Technologies Inc 952.88%$ 952.885 millions
Foghorn Therapeutics Inc 924.69%$ 924.690 millions
Zymeworks Inc 828.73%$ 828.732 millions
Abeona Therapeutics Inc 706.88%$ 706.878 millions
Brightspring Health Services Inc 588.43%$ 588.428 millions


About Ibio Inc Revenue Growth Rates (IBIO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ibio Inc (CIK 1420720).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001420720-26-000036
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ibio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.